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Abstract
Mycobacterium tuberculosis (Mtb) remains a major public health problem, with an effective vaccine continuing to prove
elusive. Progress in vaccination strategies has been hampered by a lack of appreciation of the bacterium’s response to
dynamic changes in the host immune environment. Here, we utilize reporter Mtb strains that respond to specific host
immune stresses such as hypoxia and nitric oxide (hspX9::GFP), and phagosomal maturation (rv2390c9::GFP), to investigate
vaccine-induced alterations in the environmental niche during experimental murine infections. While vaccination
undoubtedly decreased bacterial burden, we found that it also appeared to accelerate Mtb’s adoption of a phenotype
better equipped to survive in its host. We subsequently utilized a novel replication reporter strain of Mtb to demonstrate
that, in addition to these alterations in host stress response, there is a decreased percentage of actively replicating Mtb in
vaccinated hosts. This observation was supported by the differential sensitivity of recovered bacteria to the front-line drug
isoniazid. Our study documents the natural history of the impact that vaccination has on Mtb’s physiology and replication
and highlights the value of reporter Mtb strains for probing heterogeneous Mtb populations in the context of a complex,
whole animal model.
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Introduction
The potential impact that an effective vaccine against Myco-
bacterium tuberculosis (Mtb) would have in tuberculosis-endemic
countries is undisputed, yet the route towards the development of
such a vaccine has remained elusive. Most vaccine development
strategies involve the use of recombinant Bacille Calmette-Gue´rin
(BCG) expressing Mtb antigens, or BCG in combination with
boosting the immune response with Mtb protein-adjuvant mixes
or virally-encoded antigens [1–5]. None of these candidate
vaccines, nor immunity following natural infection, effectively
protects against infection or re-infection [6,7]. Vaccine candidates
that do show ‘‘efficacy’’ are able to reduce bacterial burden and
pathology, but unfortunately do not prevent the infection
establishing a stable ‘‘steady-state’’, defined as a persistent,
constant population of viable Mtb [8].
Much of the research in this area has focused on the nature of
the immune response with respect to T-cell subsets, cytokine
production, and the up-regulation of macrophage killing
responses (see for example [2–4]). Few studies have attempted
to elucidate the response of the pathogen to the host’s immune
environment, beyond the quantification of viable, persistent
bacilli. Mtb causes a chronic infection that endures in its host
and, in modern man, absent additional risk factors, only 5–10%
of infected individuals will progress to active disease [9–12]. Not
only has Mtb evolved to persist in the presence of a robust
immune response, it actually requires that immune response to
mediate the late stage damage necessary for completion of its life
cycle and transmission to new hosts [9,13,14]. The basis of this
ability appears to lie in the localized nature of the tissue response
to infection, the granuloma. While an individual may have a
robust systemic immune response, the consequences of that
response, when translated through the granuloma, can have a
range of different outcomes. Disease progression appears to be
determined at the level of the individual granuloma, to such an
extent that even in an individual who has active disease,
granulomas in all states of development from cavitation to
mineralization and resolution can be found [15,16]. The
bacterium’s ability to maintain the infection even in the face of
a strong immune response, through the localized manipulation of
host tissue, represents an extraordinary challenge to successful
vaccine development.
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One of the areas that have been seriously neglected in
understanding the basis of immune control of Mtb is the
determination of the physiological status of the bacterium within
these heterogeneous tissue environments. To address this, we have
developed a range of bacterial stress and replication reporters that
enable us to assess the fitness of Mtb in the context of its tissue
environment. We have exploited these reporter strains to probe
the infection sites in naı¨ve and vaccinated murine models in both
wild type and specific, immune-deficient mice. We found an
apparent acceleration in Mtb’s environmental niche progression in
the presence of vaccination, as reflected in differences in reporter
GFP fluorescence induction in vaccinated versus naı¨ve hosts over a
time course of infection. We also observed differences in the
replication status and the isoniazid tolerance of Mtb recovered
from vaccinated versus naı¨ve host lungs. These results demonstrate
the marked heterogeneity of the Mtb population during infection,
and provide new insights into the dynamic nature of the host
immune response as it impacts bacteria fitness and replication.
Results and Discussion
Intraperitoneal vaccination with heat-killed Mtb lowers
bacterial burden and decreases lung pathology in mice
In order to examine how Mtb responds to dynamic changes in
the host immune environment, we first established the appropriate
vaccination and challenge parameters in a murine infection model.
C57BL/6J mice were injected intraperitoneally with 56105 CFUs
of heat-killed Erdman Mtb or PBS (mock-treated), prior to
intranasal challenge four weeks later with 103 Erdman Mtb. We
chose to use heat-killed Erdman Mtb rather than BCG as the
vaccination organism, to achieve the closest antigenic match
between the vaccine and challenge bacteria. At various times post-
challenge, mice were sacrificed and bacterial burden in the lungs
determined. Although there was no, or only slight, differences in
the CFUs recovered from the lungs of vaccinated versus mock-
treated mice at 7 and 14 days post-challenge, lower bacterial
burdens were observed in the immunized mice at 21, 28 and 42
days post-challenge (Figure 1A). At 56 days post-challenge, the
bacterial burdens in the lungs of vaccinated versus mock-treated
mice were comparable (Figure 1A). In accord with the CFU data,
the lungs of Mtb-challenged immunized mice showed decreased
cellular infiltration and tissue damage (Figure 1B). These results
show that intraperitoneal vaccination with heat-killed Mtb leads to
accelerated control of subsequent Mtb challenge, lowers bacterial
burden, and reduces pathology associated with Mtb infection in
mice lungs. The kinetics of infection progression in this
experimental model of immune-mediated control provides a
manipulable system for probing the impact of vaccine-induced
immune responses on bacterial physiology and replication.
The use of fluorescent reporter strains of Mtb to probe
the host environment
Reporter Mtb strains serve as powerful tools to facilitate
dynamic analyses of Mtb’s response to its host environment at the
level of the individual bacterium, within a complex whole animal
model [17]. The reporter strains were constructed to express
mCherry constitutively (smyc9::mCherry) to enable the visualiza-
tion of all bacteria, in addition to the expression of GFP under the
regulation of promoters of characterized responsiveness [17].
While we accept that the in vivo stresses examined are likely more
complex than the in vitro induction conditions used to character-
ize the reporter constructs, the use of a diverse panel of reporter
strains generates a coherent body of data that provide insights into
the kinetics of the immune-mediated stresses experienced by Mtb
during the course of infection.
We had previously shown that pH and Cl2 act as synergistic
cues for Mtb during host colonization, with changes in these
environmental signals reflecting the immune status of the host cell
[17]. To begin examining how vaccination impacts Mtb’s
physiology during establishment of infection, we exploited a pH
and Cl2-responsive reporter strain of Mtb, Erd-
man(rv2390c9::GFP, smyc9::mCherry) [17], to challenge vaccinat-
ed and mock-treated mice. Mice were sacrificed at specific time
points post-challenge, and the lungs fixed and examined by
confocal microscopy. We observed relatively high rv2390c9::GFP
induction in Mtb-infected mock-treated mice lungs on days 14 and
28 post-challenge, which decreased at later time-points (Figur-
es 2A and 2B). In contrast, rv2390c9::GFP fluorescence was
significantly lower in vaccinated mice at the earlier time points (14
and 28 days post-challenge), with this lower level fluorescence
maintained through the course of infection (Figures 2A and 2B).
On initial examination, these results appear counter-intuitive.
The data suggest that in mock-treated mice, Mtb initially
encounters a high [Cl2]/low pH environment indicative of
enhanced phagosomal maturation, which trends towards a lower
[Cl2]/higher pH environment as the infection progresses. This
indication of early stress during the establishment of infection is
consistent with published studies in both macrophage and murine
infections, which indicate that bacteria coming from broth culture
have to re-align their physiology to be compatible with intracel-
lular survival [18,19]. During this adjustment period, rapidly
growing organisms survive poorly [18,19]. The confounding
observation is that this early expression, or presence of
rv2390c9::GFP, is absent in the vaccinated mice. The reduction
in expression of rv2390c9::GFP in the presence of an acquired
immune response, observed in the current study, may be best
explained by either of two mechanistically-divergent scenarios.
Firstly, while the adjustment in bacterial physiology required to
support intracellular survival may come at a cost with respect to
bacterial numbers, the re-alignment of bacterial physiology in the
surviving bacteria may be accelerated by the presence of a pre-
existing immune response to Mtb. Or, secondly, that bacilli
expressing higher levels of rv2390c9::GFP may be the very
bacteria that are killed most effectively by the pre-existing immune
Author Summary
Mycobacterium tuberculosis (Mtb) remains a serious chal-
lenge to global health, a situation that is exacerbated by
emerging drug resistance, the paucity of new antibiotics,
and the absence of an effective vaccine. Whilst there is no
doubt that an anti-tuberculosis vaccine would have an
extraordinary impact on the control of this disease, it is not
clear if such a goal is achievable. One major deficiency in
our knowledge is an appreciation of how the same
protective immune response that limits bacterial growth
is also responsible for driving adaptation of Mtb towards
successful maintenance of long-term infection. We have
used our panel of reporter Mtb strains that fluoresce under
different environmental stresses for experimental infec-
tions of naı¨ve and vaccinated, wild type and immune-
deficient, mouse strains. In addition, we utilized a novel
replication reporter strain to visualize the distribution of
replicating versus non-replicating bacteria within infected
lung tissue. The data provide novel insights into how the
host immune response impacts bacterial fitness, physiol-
ogy, and growth rates during the course of infection in
naı¨ve and vaccinated mice.
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response. Although the underlying mechanisms may differ the
outcome is the same; the accelerated generation of a bacterial
population better equipped to survive in its host.
The experiments described above were conducted with ‘‘non-
induced’’ bacteria. To test whether the state of induction of the
reporter fluorophore impacted outcome, we challenged vaccinated
or mock-treated mice with Erdman(rv2390c9::GFP, smyc9::m-
Cherry) pre-induced for GFP expression by growth in the presence
of 250 mM NaCl prior to infection. Pre-induction of
rv2390c9::GFP did not alter the result, with Mtb in vaccinated
mice once again exhibiting lower levels of rv2390c9::GFP
fluorescence at early time points (Figure S1). There were no
significant differences in the rv2390c9::GFP fluorescence levels of
Mtb in mock-treated mice receiving either pre-induced or
untreated Erdman(rv2390c9::GFP, smyc9::mCherry) (Figure S1).
These results confirm that rv2390c9::GFP expression is under
tight control and that even when pre-induced, the reduction in the
level of expression, or relative numbers of rv2390c9::GFP-positive
bacteria, is accelerated in the presence of a pre-existing immune
response against Mtb.
Vaccination alters the dynamics of nitric oxide
production and/or hypoxia in the microenvironment
surrounding Mtb
The results with the rv2390c9::GFP reporter imply that, at least
at the population level, the presence of an immune response
accelerates Mtb’s adoption of a physiological state conducive to
maintenance of infection, albeit at a severe cost to bacterial
survival. However, a pre-existing immune response also means the
presence of robust CD4+ and CD8+ T-cell populations capable of
activating macrophages to expresses anti-microbial activities such
as reactive oxygen (ROI) and nitrogen (RNI) intermediates [8,20].
hspX is one of the most highly up-regulated genes belonging to the
dos regulon that is expressed in response to hypoxia and nitric
oxide (NO) [21–24], and is known to be a useful correlate of the
acquired immune response. We therefore utilized an Erd-
man(hspX9::GFP, smyc9::mCherry) reporter strain [17] to probe
the kinetics of inducible nitric oxide synthase (iNOS) expression
and the bacterium’s response in both naı¨ve and vaccinated mice.
In marked contrast to rv2390c9::GFP expression, very low levels
of hspX9::GFP fluorescence are seen initially, with extremely
strong induction of hspX9::GFP fluorescence observed 4 weeks
post-infection. These kinetics correlate with the establishment of
an adaptive immune response, specifically IFNc and iNOS
production (Figures 3A and 3B) [8,17]. Strikingly, we observed
higher levels of hspX9::GFP fluorescence in Mtb present in
vaccinated versus mock-treated mice at 14 days post-challenge
(Figures 3A and 3B). hspX9::GFP fluorescence increased further at
28 days post-challenge in the vaccinated mice; however the levels
of fluorescence induction in mock-treated mice now matched, and
even surpassed, the levels observed in the vaccinated mice at this
time point (Figures 3A and 3B), in accord with the establishment
of an acquired immune response in the mock-treated mice and its
effect on the hspX9::GFP reporter [8,17]. These high levels of
hspX9::GFP fluorescence were maintained at days 42 and 56 post-
challenge in both groups of mice (Figures 3A and 3B).
To determine if the elevated levels of hspX9::GFP fluorescence
in vaccinated mice correlated with both levels and distribution of
iNOS expression, we stained the lung tissue sections with an
antibody against murine iNOS. Consistent with data from
previous studies [25,26], the majority of the lung tissues analyzed
from mock-treated mice at 14 days post-challenge were almost
uniformly negative for iNOS. A rare iNOS-positive region in the
mock-treated mice lung tissue is shown in Figure 3C. In contrast,
iNOS-positive regions were frequent in lung tissue from Mtb-
infected vaccinated mice at day 14 post-challenge (Figure S2). As
reported previously, we observed greater hspX9::GFP fluorescence
in Mtb residing in iNOS-positive versus iNOS-negative regions
within the same lung tissue (Figures 3C and 3D) [17]. These data
demonstrate, not surprisingly, that vaccination promotes an early
onset of adaptive immune responses, and a correspondingly
accelerated production of iNOS. These results provide the
Figure 1. Characterization of a heat-killed Mtb vaccination model. (A) Kinetics of Mtb colonization in vaccinated or mock-treated mice lungs.
C57BL/6J mice were intraperitoneally injected with 56105 CFUs of heat-killed Erdman or with sterile PBS (mock-treated). Four weeks post-
vaccination, mice were challenged with 103 CFUs of various reporter Mtb intranasally. At indicated time points post-challenge, mice were sacrificed
and the bacterial burden in the lungs determined. The pooled data for each time point are shown as means 6 SEM, from at least 3 animals per data
point. * indicates p,0.05 (unpaired t-test). (B) Lung pathology of vaccinated and mock-treated mice. Lungs collected at indicated time points post-
challenge were fixed in 4% paraformaldehyde and subjected to routine H&E staining. Scale bar 200 mm.
doi:10.1371/journal.ppat.1004394.g001
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Figure 2. Differences in expression of rv2390c9::GFP in Mtb present in vaccinated versus mock-treated mice. Erdman(rv2390c9::GFP,
smyc9::mCherry) was inoculated into vaccinated or mock-treated C57BL/6J WT mice for up to 56 days. (A) shows 3D confocal images from a 14, 28, or
42 day infection. All bacteria are marked in red (smyc9::mCherry), reporter signal is shown in green (rv2390c9::GFP), nuclei are marked in grayscale
(DAPI), and phalloidin staining of f-actin is shown in blue. Scale bar 10 mm. (B) shows quantification of the GFP/mm3 signal for each bacterium
measured from multiple 3D confocal images, at the indicated time points. Each point on the graph represents a bacterium or a tightly clustered
group of bacteria (mock-treated – filled symbols, vaccinated – open symbols). Horizontal lines mark the median value for each group. p-values were
obtained with a Mann-Whitney statistical test.
doi:10.1371/journal.ppat.1004394.g002
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bacterium’s perspective to the kinetics of development of an
acquired immune response and the imposition of RNI-mediated
stress at the level of the infected tissue.
Utilization of select immune-deficient mice to
demonstrate the specificity of Mtb’s response to
immune-mediated stress
To further validate the specificity of Mtb’s responses to
vaccination-induced alterations of the immune microenvironment,
we probed the behavior of the fluorescent reporter strains in a
select panel of immune-deficient mice. In the absence of IFNc,
Mtb-infected mice fail to activate macrophages or produce
reactive nitrogen intermediates, resulting in unrestricted growth
of Mtb and fatality [27,28]. We have previously shown that there
is significantly lower reporter Mtb GFP fluorescence in IFNc2/2
mice infected with Erdman(rv2390c9::GFP, smyc9::mCherry) or
Erdman(hspX9::GFP, smyc9::mCherry), consistent with the concept
that Mtb infecting IFNc2/2 hosts are present in less hostile
microenvironments [17]. Here, we vaccinated IFNc2/2 mice and
challenged them with the different reporter Mtb strains, to
determine the role of IFNc in vaccination-induced modulation of
Mtb’s microenvironment. We restricted these studies to the first 28
days post-challenge, as mock-treated IFNc2/2 mice succumb to
Mtb infection early.
At 14 days post-challenge we observed no differences in Mtb
CFUs recovered from either mock-treated or vaccinated IFNc2/2
mice, while at 28 days post-challenge, although not statistically
significant, the vaccinated mice harbored lower bacterial CFUs as
compared to the mock-treated IFNc2/2 mice (Figure 4A). This is
consistent with a previous study that showed decreased bacterial
burden and enhanced median survival of Mtb-infected IFNc2/2
mice on BCG vaccination [29]. In contrast to what was observed
for WT mice, there was higher rv2390c9::GFP fluorescence in
Mtb present in vaccinated versus mock-treated IFNc2/2 mice at
both time points tested (days 14 and 28 post-challenge) (Figures 4B
and 4C). These data suggest that in the absence of an acquired
immune response that includes IFNc, the stress from components
of the innate response, as indicated by rv2390c9::GFP expression,
endures longer, or, alternatively, clearance of the rv2390c9::GFP-
expressing bacteria is delayed.
With Erdman(hspX9::GFP, smyc9::mCherry), we observed sig-
nificantly lower levels of reporter Mtb GFP fluorescence in
IFNc2/2 mice as compared to WT mice, irrespective of treatment
(Figures 5A and 5B), consistent with iNOS expression being the
major inducer of hspX9::GFP expression. Despite this clear
difference in the absolute levels of induction, the trends in
hspX9::GFP fluorescence between the vaccinated and the mock-
treated mice were similar in both WT and IFNc2/2 mice, with
higher GFP signal in Mtb present in vaccinated versus mock-
treated IFNc2/2 mice at 14 days post-challenge (Figures 5A and
5B). These data indicate that the induction of fluorescence in these
reporter strains should not be viewed as a consequence solely of
expression of enzymes such as iNOS.
To probe this phenomenon more deeply, we utilized NOS22/2
mice to determine the dynamics of hspX9::GFP expression in the
absence of iNOS. We observed a slightly lower bacterial burden in
vaccinated versus mock-treated NOS22/2 mice, although the
differences were not statistically significant (Figure 5C). Similar to
IFNc2/2 mice, hspX9::GFP fluorescence was present at very low
levels in Mtb present in NOS22/2 mice (Figures 5A and 5B).
While no differences in Mtb hspX9::GFP reporter fluorescence was
observed at 14 days post-challenge in NOS22/2 mice, lower
hspX9::GFP fluorescence was seen in vaccinated versus mock-
treated NOS22/2 mice at 28 days post-challenge (Figures 5A and
5B). The results with the NOS22/2 mice confirm that, while other
factors impact this bacterial reporter strain, NO is the major driver
of hspX expression in Mtb within the murine model.
Vaccination decreases the percentage of actively
replicating Mtb
Figure 1 clearly demonstrates that vaccination reduces the
number of viable bacteria present in the mouse when the infection
first transitions to ‘‘steady state’’. However, the dynamic nature of
this population is not well understood. To what extent does this
represent overlapping curves of replication versus death, and to
what extent does this represent limited bacterial replication? While
this question has been studied at the population level, the degree of
heterogeneity within that population is unknown. To extend the
data from the reporter strains, we sought to determine the effect of
vaccination on Mtb’s replication status, at the level of the
individual bacillus. For this purpose we constructed a replication
reporter, Erdman(SSB-GFP, smyc9::mCherry), consisting of a
fusion of single stranded binding protein (SSB) to GFP, present
on a replicating plasmid containing a constitutively expressed
mCherry. In Escherichia coli, fluorescent tagging of components of
the replisome, such as SSB, marks DNA replication initiation by
the appearance of a replisome focus, which can be tracked through
DNA replication, with foci disappearance upon termination of
DNA replication [30]. SSB-fluorophore fusions have also been
validated extensively as a marker of active DNA replication in
Bacillus subtilis [31,32]. We established the dynamics of SSB-GFP
expression using live-cell time-lapse microscopy of Mycobacterium
smegmatis expressing the replication reporter construct. As
anticipated, the SSB-GFP reporter defined cell cycle timing, with
SSB-GFP foci present for periods of DNA replication (Figure 6A
and Video S1). As in E. coli and B. subtilis, we observed that SSB-
GFP foci disappeared when the bacteria stopped growing (such as
during stationary phase). Consistent with the duration of the SSB-
GFP foci in replicating M. smegmatis, we also observed that 76%–
80% of log-phase broth cultures of Mtb exhibited SSB-GFP foci.
CFU enumeration provides population-based information on the
numbers of surviving Mtb within the host, but does not provide
Figure 3. Differences in expression of hspX9::GFP in Mtb present in vaccinated versus mock-treated mice. (A and B) Higher hspX9::GFP
induction in vaccinated mice at 14 days post-challenge. Erdman(hspX9::GFP, smyc9::mCherry) was inoculated into vaccinated or mock-treated C57BL/
6J WT mice for up to 56 days. (A) shows 3D confocal images from a 14, 28, or 42 day infection. All bacteria are marked in red (smyc9::mCherry),
reporter signal is shown in green (hspX9::GFP), nuclei are marked in grayscale (DAPI), and phalloidin staining of f-actin is shown in blue. Scale bar
10 mm. (B) shows quantification of the GFP/mm3 signal for each bacterium measured from multiple 3D confocal images, at the indicated time points.
Each point on the graph represents a bacterium or a tightly clustered group of bacteria (mock-treated – filled symbols, vaccinated – open symbols).
Horizontal lines mark the median value for each group. p-values were obtained with a Mann-Whitney statistical test. (C and D) hspX9::GFP-positive
Mtb reside in iNOS-positive mouse lung regions. Erdman(hspX9::GFP, smyc9::mCherry) was inoculated into vaccinated or mock-treated C57BL/6J WT
mice for 14 days. (C) shows 3D confocal images, with all bacteria marked in red (smyc9::mCherry), reporter signal shown in green (hspX9::GFP), iNOS
stained in magenta, nuclei marked in grayscale (DAPI), and phalloidin staining of f-actin shown in blue. Scale bar 10 mm. (D) shows quantification of
the bacterial GFP/mm3 signal, measured as in (B), in Mtb present in iNOS-positive versus negative regions. Horizontal lines mark the median value for
each group. p-values were obtained with a Mann-Whitney statistical test.
doi:10.1371/journal.ppat.1004394.g003
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insight into population heterogeneity in the context of Mtb’s tissue
environment. We note that the lack of SSB-GFP foci in a cell may
indicate either a non-growing bacterium, or mark a growing cell
not in the active stage of DNA replication. Time point-based
experiments with the Erdman(SSB-GFP, smyc9::mCherry) reporter
strain will thus present snapshots that allow us to visualize the
heterogeneity in replication status within the bacterial population,
as well as to quantify active DNA replication at the level of the
individual bacterium.
WT and IFNc2/2 mice were vaccinated or mock-treated, 4
weeks before challenge with Erdman(SSB-GFP, smyc9::m-
Cherry). At 14 days post-challenge, there was marked hetero-
geneity in the percentage of actively replicating Mtb even within
treatment groups, and no statistically significant differences
between Mtb in vaccinated and mock-treated WT and IFNc2/2
mice were observed (Figure 6B). However, distinct differences in
the replication status of Mtb between experimental groups were
seen at 28 days post-challenge (Figures 6C and 6D). Confocal
microscopy revealed significantly fewer Mtb exhibiting SSB-
GFP foci in vaccinated versus mock-treated WT mice (6.4%
versus 39.5% respectively, p = 0.0002) (Figures 6C and 6D).
Consistent with the increased growth of Mtb in IFNc2/2 mice
at 28 days post-challenge, we observed a greater number of
bacteria positive for SSB-GFP foci in these mice (67.1% versus
39.5% for mock-treated WT versus IFNc2/2 mice, p = 0.0004)
(Figures 6C and 6D). Similar to WT mice however, a lower
percentage of Mtb present in vaccinated IFNc2/2 mice
exhibited SSB-GFP foci versus mock-treated IFNc2/2 mice,
although we did not have statistical significance in this case
(51.6% versus 67.1%, p = 0.052) (Figures 6C and 6D). These
results indicate that vaccination leads to a decreased percentage
of actively-replicating Mtb in the host.
Differential drug susceptibility of Mtb supports the
growth profiles indicated by the replication reporter
The replication status of Mtb is reflected in its differential
sensitivity to drugs. Isoniazid (INH) inhibits mycolic acid synthesis,
which is required for cell wall synthesis and shows preferential
activity against actively replicating organisms, while rifampicin
(Rif) inhibits DNA-dependent RNA polymerase and shows more
similar levels of activity against replicating and static organisms
[33,34]. Comparative differences in the tolerance of Mtb to INH
and Rif are commonly utilized to assess the growth state of Mtb
[35,36].
Figure 4. Dynamics of rv2390c9::GFP induced fluorescence in immune-deficient vaccinated versus mock-treated mice. (A) Bacterial
burden in vaccinated and mock-treated IFNc2/2 mice. Reporter Mtb strains were inoculated into vaccinated or mock-treated C57BL/6J IFNc2/2 mice
for up to 28 days. CFUs were determined by plating lung homogenates at 14 or 28 days post-challenge (mock-treated – filled symbols, vaccinated –
open symbols). Horizontal lines mark the median value for each group. p-values were obtained with a Mann-Whitney statistical test. (B and C)
rv2390c9::GFP induced fluorescence in vaccinated or mock-treated WT versus IFNc2/2 mice. Erdman(rv2390c9::GFP, smyc9::mCherry) was inoculated
into vaccinated or mock-treated C57BL/6J WT or IFNc2/2 mice for up to 28 days. (B) shows 3D confocal images from a 14 day infection, with all
bacteria marked in red (smyc9::mCherry), reporter signal shown in green (rv2390c9::GFP), nuclei marked in grayscale (DAPI), and phalloidin staining of
f-actin shown in blue. Scale bar 10 mm. (C) shows quantification of the GFP/mm3 signal for each bacterium measured from multiple 3D confocal
images, at the indicated time points. Each point on the graph represents a bacterium or a tightly clustered group of bacteria (mock-treated – filled
symbols, vaccinated – open symbols; WT mice infections – black, IFNc2/2 mice infections - red). Data for WT mice infections are as shown in
Figure 2B. Horizontal lines mark the median value for each group. p-values were obtained with a Mann-Whitney statistical test.
doi:10.1371/journal.ppat.1004394.g004
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Figure 5. Dynamics of hspX9::GFP induced fluorescence in immune-deficient vaccinated versus mock-treated mice. (A and B)
hspX9::GFP induced fluorescence in vaccinated or mock-treated IFNc2/2 and NOS22/2 mice. Erdman(hspX9::GFP, smyc9::mCherry) was inoculated into
vaccinated or mock-treated C57BL/6J WT, IFNc2/2, or NOS22/2 mice for up to 28 days. (A) shows 3D confocal images from a 14 day infection, with all
bacteria marked in red (smyc9::mCherry), reporter signal shown in green (hspX9::GFP), nuclei marked in grayscale (DAPI), and phalloidin staining of f-
actin shown in blue. Scale bar 10 mm. (B) shows quantification of the GFP/mm3 signal for each bacterium measured from multiple 3D confocal images,
at the indicated time points. Each point on the graph represents a bacterium or a tightly clustered group of bacteria (mock-treated – filled symbols,
vaccinated – open symbols; WT mice infections – black, IFNc2/2 mice infections – red, NOS22/2 mice infections - blue). Data for WT mice infections
are as shown in Figure 3B. Horizontal lines mark the median value for each group. p-values were obtained with a Mann-Whitney statistical test. (C)
Bacterial burden in vaccinated and mock-treated NOS22/2 mice. Erdman(hspX9::GFP, smyc9::mCherry) was inoculated into vaccinated or mock-treated
NOS22/2 mice for up to 28 days. CFUs were determined by plating lung homogenates at 14 or 28 days post-challenge (mock-treated – filled symbols,
vaccinated – open symbols). Horizontal lines mark the median value for each group. p-values were obtained with a Mann-Whitney statistical test.
doi:10.1371/journal.ppat.1004394.g005
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Figure 6. Mtb replication in vaccinated versus mock-treated mice. (A) SSB-GFP defines cell cycle timing in M. smegmatis. SSB-GFP expressing
M. smegmatis cells were imaged every 15 minutes while growing in a microfluidic device (as described in [38]) in 7H9 supplemented with 10% ADC,
0.2% glycerol, 0.05% Tween 80, and 50 mg/ml hygromycin B. The medium was further supplemented with 2% DMSO and 0.0625 mg/ml FM4-64 FX to
visualize septal membranes. The number of SSB-GFP foci (gray, inside of the chart) indicates the status of DNA replication in single cells. The average
time in each period of the cell cycle is indicated (n = 122). B (G1) is the period after division but before initiation of DNA replication, C (S) is the period
of DNA replication, and D (G2) is the period between the termination of DNA replication and division (defined as cell wall pinching or v-snapping).
Some cells begin a new round of replication before division; daughters of these cells do not spend time in B. Standard deviations are 19, 38, 26, and
13 minutes for B, C, D, and pre-division replication, respectively. (B–D) Erdman(SSB-GFP, smyc9::mCherry) was inoculated into vaccinated or mock-
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We collected lung homogenates from either vaccinated or
mock-treated mice at various time-points and incubated them with
0.4 mg/ml of INH or Rif, or DMSO as a control, for 24 hours,
before plating to determine CFUs of surviving bacteria. We
observed a gradual increase in INH tolerance of Mtb recovered
from mock-treated mice as the infection progressed from 7 to 28
days post-challenge, while Rif tolerance remained unchanged
(Figure 7A). Most notably, Mtb recovered at 14 days post-
challenge from vaccinated mice displayed greater tolerance to
INH but not Rif (Figure 7B); however, this differential drug
sensitivity was lost by day 28 post-challenge (Figure 7C). These
results suggest that vaccination, through the accelerated acquisi-
tion of an acquired immune response, leads to immune-mediated
control of bacterial replication; a finding consistent with the data
generated by the Erdman(SSB-GFP, smyc9::mCherry) replication
reporter strain.
Conclusions
While there is an extensive body of literature exploring the
nature of the immune response to Mtb from the host’s perspective,
few studies, beyond those analyzing the phenotypes of Mtb
mutants, have attempted to address the infection process from the
perspective of the bacterium. And yet this infection represents an
exquisite balance between persistence and disease in which both
host and pathogen play equally critical roles. While it is true that
the mouse is not ideal as a model for the progression of human
disease, it is an important tool for validation of new reagents and
probes such as the reporter strains characterized in this current
study.
Data in this study illustrate the dynamics of Mtb fitness and
adaptation in a vaccinated versus naı¨ve host immune environ-
ment. While vaccination with heat-killed Mtb clearly reduced the
bacterial burden at onset of immune-mediated control, it also
appeared to either accelerate the resolution of the innate immune
stresses experienced by Mtb early in infection, or accelerate
‘‘purification’’ of the population and the death of those bacilli least
physiologically-adapted to survive. The results with the SSB-GFP
replication reporter and tests on INH and Rif tolerance also
suggest a hastened onset of a more persistent stage of Mtb
colonization in the presence of vaccination. These findings raise
questions about the feasibility of developing a sterilizing vaccine,
and on the impact of a non-sterilizing vaccination on the
progression of a subsequent Mtb infection. Is sterilizing immunity
via vaccination achievable considering Mtb’s exquisite ability to
resist clearance in the face of an activated immune system? Are
there possible adverse impacts on subsequent Mtb infection that
may be prompted by a non-sterilizing vaccination? We feel that
these are fundamental issues that should be considered in the
development of Mtb vaccination and treatment strategies.
Our experiments further demonstrate the utility of reporter Mtb
strains for the in vivo analysis of host-pathogen interactions [17].
In addition to reporter Mtb strains responsive to defined host
environmental cues such as pH and NO [17], we have validated a
novel Mtb replication reporter, SSB-GFP, which enable determi-
nation of Mtb’s replication status at the level of the individual
microbe and its site of infection. This is particularly significant as
other methods for assessing Mtb replication, such as the use of a
‘‘clock’’ plasmid that is lost from replicating bacilli at a fixed rate
[18], allows monitoring of Mtb replication at the population level,
but cannot place replication status in the spatial context of Mtb’s
microenvironment. Coupling the use of these reporters with
confocal microscopy and careful quantification of individual
bacteria allowed Mtb’s heterogeneous response to the dynamic
host immune system to be evaluated. Studies using rabbit or
macaque models of Mtb infection have previously reported the
lesion to lesion heterogeneity that exists within the lungs of a single
animal, with the progression and fate of each lesion being
independent [15,16]. Our study shows that heterogeneity during
Mtb infection is present not just at the level of the host tissue, but is
also a function across the population of infecting bacteria. The
degree to which this bacterial heterogeneity ‘‘prepares’’ Mtb to
exploit the diverse and evolving tissue environments of the host is a
challenging question but one rendered more accessible through
the reporter strains detailed here. We believe that this marked
heterogeneity is biologically significant and propose that further
studies exploiting such reporter tools in appropriate animal models
will yield new insights into the factors that tip the host/pathogen
balance.
Materials and Methods
Ethics statement
Animal procedures were performed in strict accordance with
the National Institutes of Health ‘‘Guide for the Care and Use of
Laboratory Animals’’, and with the approval of the Institutional
Animal Care and Use Committee of Cornell University (protocol
number 2011-0086). All efforts were made to minimize suffering.
Fluorescent reporter Mtb strains
Erdman(smyc9::mCherry) was generated by transforming Erd-
man WT with the replicating plasmid pCherry3, and selecting for
transformants on 7H10 agar containing 50 mg/ml hygromycin B
[37]. Erdman(rv2390c9::GFP, smyc9::mCherry) and Erd-
man(hspX9::GFP, smyc9::mCherry) have been previously described
[17]. To generate Erdman(SSB-GFP, smyc9::mCherry), a 334 bp
region immediately upstream of ssb together with the ssb open
reading frame (excluding the stop codon) was PCR amplified from
Mtb genomic DNA. This was fused to gfpmut2 amplified from the
vector pSE100, by overlapping PCR. An 11 amino acid linker
region (SAGSAAGSGEF) was included between the ssb and
gfpmut2 open reading frames, to help prevent interference of SSB
function by GFP [30]. This construct was subcloned into
pCherry3 and transformed into Erdman Mtb. Selection for
transformants was carried out on 7H10 agar containing 50 mg/
ml hygromycin B. The reporter Mtb strains were grown to log
phase in 7H9 broth supplemented with 50 mg/ml hygromycin B,
aliquoted in 10% glycerol, and stored at 280uC until use. For Mtb
infections in mice, aliquots were thawed, passed 3–5 times through
a tuberculin syringe, and diluted to the required CFUs in sterile
phosphate buffered saline (PBS) containing 0.05% Tween 80. For
treated C57BL/6J WT or IFNc2/2 mice for up to 28 days. (B) shows the percentage of Mtb displaying SSB-GFP foci for each mouse, measured from
multiple 3D confocal images, at 14 days post-challenge. Each point on the graph represents a mouse (mock-treated – filled symbols, vaccinated –
open symbols; WT mice infections – black, IFNc2/2 mice infections – red). Horizontal lines mark the median value for each group. (C) shows 3D
confocal images from a 28 day infection, with all bacteria marked in red (smyc9::mCherry), reporter signal shown in green (SSB-GFP), nuclei marked in
grayscale (DAPI), and phalloidin staining of f-actin shown in blue. For clarity of foci visualization, SSB-GFP signal is shown in extended focus, overlaid
on the 3D image. Scale bar 10 mm. (D) shows the percentage of Mtb displaying SSB-GFP signal for each mouse, measured as in (B), at 28 days post-
challenge. Each point on the graph represents a mouse (mock-treated – filled symbols, vaccinated – open symbols; WT mice infections – black, IFNc2/
2 mice infections – red). Horizontal lines mark the median value for each group. p-values were obtained with a Mann-Whitney statistical test.
doi:10.1371/journal.ppat.1004394.g006
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Cl2 induction of Erdman(rv2390c9::GFP, smyc9::mCherry), the
reporter strain was grown to log phase and seeded at an OD600 of
0.05 in 7H9 media containing 250 mM NaCl, buffered at pH 7
with 100 mM MOPS. The induction was allowed to continue for
6 days, after which an aliquot was diluted in PBS containing
0.05% Tween 80 to the necessary CFUs for mice infections.
Mice vaccination and infections
6–8 week old C57BL/6J, B6.129S7-Ifngtm1Ts/J (IFNc2/2) and
B6.129P2-Nos2tm1Lau/J (NOS22/2) mice were obtained from
Jackson Laboratories. Mice were intraperitoneally injected with
56105 CFUs of heat-killed Erdman, or as control, 100 ml of PBS.
Four weeks post-vaccination, mice were intranasally challenged
with approximately 1000 CFUs of different Erdman reporter
strains in 25 ml of PBS containing 0.05% Tween 80. The inoculum
dosage was confirmed by plating different dilutions on 7H10 plates
supplemented with 50 mg/ml hygromycin B. At various times
post-challenge, mice were sacrificed and the left lung lobe and the
accessory lobe of the right lung homogenized in PBS containing
0.05% Tween 80. Bacterial loads were determined by plating
serial dilutions of the homogenates on 7H10 agar +/250 mg/ml
hygromycin B. Plates were incubated at 37uC and colonies
enumerated 3–4 weeks after. The other lobes of the right lung
were harvested, fixed overnight in 4% paraformaldehyde, and
transferred into sterile PBS until examination. All animals were
maintained in a specific pathogen-free Biosafety level-3 facility.
Lung histopathology
Paraformaldehyde fixed lung lobes were subjected to routine
hematoxylin and eosin staining by the Cornell Histology
Laboratory. Stained sections were imaged using a Zeiss Axio
Imager M1 equipped with an AxioCam HRc camera.
Confocal microscopy and quantification of reporter
expression
Processing of lung tissues for confocal microscopy and reporter
Mtb expression quantification was carried out as previously
described [17]. In brief, sections of fixed lung tissues were stained
with DAPI and Alexa Fluor 647 conjugated phalloidin (Invitro-
gen), mounted with Vectashield mounting medium (Vector Labs),
and imaged using a Leica SP5 confocal microscope. Z-stacks were
reconstructed into 3D using Volocity software (PerkinElmer), and
Mtb GFP expression quantified by simultaneously measuring the
voxel volume of each bacterium, via the mCherry channel, and
the corresponding sum of the GFP signal for that bacterium.
Images for the different reporter strains were taken with the GFP
setting fixed within experimental sets and time points to allow
comparison. At least 100 bacteria were quantified for each
condition. Quantification of the SSB-GFP reporter was accom-
plished by counting the number of bacteria with and without SSB-
GFP replication foci, and calculating the total percentage of
bacteria presenting one or more SSB-GFP foci for all regions
imaged for each animal. Lung sections from at least 5–9 mice per
treatment per time point were imaged, and at least three images
from different regions of each lung section were used for
quantification. Statistical analyses were carried out by a non-
parametric Mann-Whitney test.
Staining of iNOS was also carried out as previously described
[17]. In brief, lung sections were permeabilized and blocked for
1 hour at room temperature with blocking buffer (PBS +3%
Bovine Serum Albumin +0.1% Triton X-100). Sections were
incubated with rabbit anti-iNOS (BD Transduction Labs) at a
dilution of 1:100, overnight at 4uC. After washing with blocking
Figure 7. Mtb in vaccinated lungs display higher tolerance to
isoniazid but not rifampicin. (A) Kinetics of tolerance of Mtb to INH
and Rif in mock-treated mice. Erdman reporter strains were inoculated into
C57BL/6J WT mice for up to 28 days. Lung homogenates collected at days
7, 14 and 28 post-challenge were subjected to treatment with 0.4 mg/ml
INH or Rif, or DMSO as a control, for 18–20 hours, and the percentage of
Mtb surviving INH or Rif treatment determined. (B and C) Erdman reporter
strains were inoculated into vaccinated or mock-treated C57BL/6J WT mice
for up to 28 days. Lung homogenates collected from vaccinated or mock-
treated mice at days 14 (B) or 28 (C) post-challenge were subjected to
treatment with 0.4 mg/ml INH or Rif, or DMSO as a control, for 18–20 hours,
and the percentage of Mtb surviving INH or Rif treatment determined.
Each point on the graph represents a mouse (mock-treated – filled
symbols, vaccinated – open symbols; circle – INH treatment, square – Rif
treatment). Horizontal lines mark the median value for each group. p-
values were obtained with a Mann-Whitney statistical test.
doi:10.1371/journal.ppat.1004394.g007
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buffer, the sections were incubated with Alexa Fluor 514 goat anti-
rabbit (1:200) (Invitrogen), DAPI (1:500), and Alexa Fluor 647
conjugated phalloidin (1:50) (Invitrogen) at room temperature for
2 hours. The samples were then washed and mounted with
Vectashield mounting medium and analyzed by confocal micros-
copy.
Live-cell time-lapse imaging of M. smegmatis
M. smegmatis strain mc2155 was transformed with a SSB-GFP
replicating plasmid as described above. M. smegmatis cells
expressing SSB-GFP were grown and imaged in a microfluidic
device as previously described [38]. Images were acquired every
15 minutes for 18–24 hours, using a PersonalDV Delta Vision
widefield microscope equipped with hardware-based autofocus
and an EM-CCD camera. Low-light imaging conditions were used
to prevent phototoxicity and DNA damage. To visualize septal
membranes, the medium was supplemented with 2% DMSO and
0.0625 mg/ml FM4-64 FX (Invitrogen). Newly divided cells
generally did not have an SSB-GFP focus, and we labeled this
the pre-replication period. The period where there were 1–2 SSB-
GFP foci was defined as the replication stage, and the subsequent
period where foci were absent was labeled as the post-replication
stage. In some cells, SSB-GFP foci appeared after D but before
septation, and this stage was labeled as ‘‘pre-division replication.
Images were processed and analyzed using ImageJ, ObjectJ, and
custom software written in MATLAB R2013a.
Isoniazid and rifampicin assays
Lung homogenates (100 ml) obtained from Mtb infected
vaccinated or mock-treated mice harvested at different time points
were incubated with 0.04 mg/ml isoniazid (INH), rifampicin (Rif),
or DMSO as a control, in a total volume of 200 ml in 7H9 medium
in 96 well plates. The plates were incubated for 18–20 hours at
37uC, after which bacterial CFUs were enumerated by plating
different dilutions on 7H10 plates. The percentage of surviving
bacteria was calculated by dividing the CFUs obtained after INH
or Rif treatment by CFUs obtained after control DMSO
treatment, multiplied by 100.
Supporting Information
Figure S1 Pre-induction of rv2390c9::GFP signal does
not alter in vivo rv2390c9::GFP fluorescence. Erd-
man(rv2390c9::GFP, smyc9::mCherry) was grown in broth culture
+/2250 mM NaCl, pH 7, for 6 days prior to inoculation into
vaccinated or mock-treated C57BL/6J WT mice for 14 days. (A)
shows 3D confocal images, with all bacteria marked in red
(smyc9::mCherry), reporter signal shown in green (rv2390c9::GFP),
nuclei marked in grayscale (DAPI), and phalloidin staining of f-
actin shown in blue. Scale bar 10 mm. (B) shows quantification of
the GFP/mm3 signal for each bacterium measured from multiple
3D confocal images, at the indicated time points. Each point on
the graph represents a bacterium or a tightly clustered group of
bacteria (mock-treated – filled symbols, vaccinated – open
symbols; untreated Mtb inoculum – black, pre-induced Mtb
inoculum - red). Horizontal lines mark the median value for each
group. p-values were obtained with a Mann-Whitney statistical
test.
(TIF)
Figure S2 iNOS-positive regions are more frequent in
Mtb-infected vaccinated mice lung tissues at day 14
post-challenge. Erdman(hspX9::GFP, smyc9::mCherry) was in-
oculated into vaccinated or mock-treated C57BL/6J WT mice for
14 days. Two sets of 3D confocal images are shown for each
treatment condition, with all bacteria marked in red (smyc9::m-
Cherry), reporter signal shown in green (hspX9::GFP), iNOS
stained in magenta, nuclei marked in grayscale (DAPI), and
phalloidin staining of f-actin shown in blue. Scale bar 20 mm.
(TIF)
Video S1 Live fluorescence time-lapse of SSB-GFP
expressing M. smegmatis growth in a microfluidic
device. M. smegmatis expressing SSB-GFP (green) was grown
in a microfluidic device, in media supplemented with FM4-64 FX
for visualization of septal membranes (red). Images were collected
every 15 minutes for 12.75 hours. The movie is compressed into
10 seconds (45906 speed).
(MOV)
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